Alle Storys
Folgen
Keine Story von Occlutech GmbH mehr verpassen.

Occlutech GmbH

Occlutech prevails in U.K. patent appeal by AGA Medical

Jena (ots)

In 2009 the Patents Court of the High Court, Chancery
Division, decided that Occlutech's range of Figulla ASD and PFO 
occluders do not infringe the U.K. part of European Patent 0 808 138.
AGA Medical decided to appeal against this decision. The U.K. Court 
of Appeal (civil division) in London announced its decision 
confirming that said Figulla ASD and PFO occluders do not infringe 
said patent. AGA asked for permission to appeal to the Supreme Court 
(formerly called the House of Lords), but that application was 
refused.  It is now open to AGA to make an application direct to the 
Supreme Court for permission to appeal,  but permission is granted 
only sparingly, such as in cases that involve a point of law of 
general public importance.
Tor Peters, CEO of Occlutech says; "We are very happy with the 
courts decision that again brings clarity to Occlutech's position 
that our unique patented braiding technology is fundamentally 
different from the old technology. The flexibility and versatility of
our products and the innovative delivery systems have helped us 
obtain market leading positions in several markets and we intend to 
expand this position over the next years."
Occlutech is a private company with R&D and manufacturing 
activities in several European countries. Founded in 2003, the 
company sells its innovative ASD and PFO occluders in over 40 
countries, except Germany.
Occlusion devices are used to treat structural heart disease, 
including structural heart defects and abnormalities such as Atrial 
Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired 
channel between the heart's two atria, present in up to 25% of the 
population), in minimally invasive, non-surgical procedures. The 
market for PFO occluders is expected to expand significantly as the 
link between PFO and stroke, that is the third most common cause of 
death, as well as severe migraine becomes increasingly well 
documented.

Contact:

Tor Peters
info@occlutech.de
Tel: +49 3641 67 51 29

Katrin Biedermann
katrin.biedermann@occlutech.de
Tel.: +49 3641 67 51 20

Weitere Storys: Occlutech GmbH
Weitere Storys: Occlutech GmbH
  • 23.09.2009 – 17:24

    Occlutech Receives Positive Ruling in German Proceeding Initiated by AGA Medical

    Jena, Germany (ots/PRNewswire) - Occlutech GmbH, the leading European developer of products for septal closure, today announced that the district court of Frankfurt, Germany reversed an earlier court injunction obtained by AGA Medical against Occlutech's sales and marketing activities relating to the newly launched Figulla Flex ranges of ASD and PFO occluders. ...

  • 12.05.2009 – 09:51

    Occlutech obtains CE mark for the new generation PFO & ASD occluders

    Jena (ots) - Occlutech, the leading European developer of septum occluders, today announced that it has obtained CE mark approval for its new generation ASD and PFO occluders, the Figulla Flex. The Figulla Flex ASD and PFO occluders encompass a new innovative delivery system, making the use of a threaded hub unnecessary. The implantation of the occluder is facilitated by the ability of the delivery system to ...

  • 19.03.2009 – 10:43

    Occlutech obtains favourable ruling in proceedings initiated by AGA Medical

    Jena (ots) - Occlutech GmbH today announced that it had defeated a request for insolvency, launched at the Amtsgericht Gera in Germany by its US competitor AGA Medical. The request by AGA was based on wrongful assumptions about Occlutech, and AGA announced that it had started the said request to recover damages. However, the court - Amtsgericht Gera in ...